0001544927-23-000001.txt : 20231122 0001544927-23-000001.hdr.sgml : 20231122 20231122104512 ACCESSION NUMBER: 0001544927-23-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20231122 DATE AS OF CHANGE: 20231122 EFFECTIVENESS DATE: 20231122 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alcyone Therapeutics, Inc. CENTRAL INDEX KEY: 0001544927 IRS NUMBER: 274036551 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-497946 FILM NUMBER: 231430641 BUSINESS ADDRESS: STREET 1: 250 JACKSON STREET STREET 2: UNIT 494, MILL NO. 5 BUILDING CITY: LOWELL STATE: MA ZIP: 01852 BUSINESS PHONE: 781-929-6094 MAIL ADDRESS: STREET 1: 250 JACKSON STREET STREET 2: UNIT 494, MILL NO. 5 BUILDING CITY: LOWELL STATE: MA ZIP: 01852 FORMER COMPANY: FORMER CONFORMED NAME: Alcyone Lifesciences, Inc. DATE OF NAME CHANGE: 20120315 D 1 primary_doc.xml X0708 D LIVE 0001544927 Alcyone Therapeutics, Inc. 116 John Street Suite 300 LOWELL MA MASSACHUSETTS 01852 978-709-1946 DELAWARE Alcyone Lifesciences, Inc. Corporation true PJ Anand 116 John Street Suite 300 Lowell MA MASSACHUSETTS 01852 Executive Officer Director Richard Upton 116 John Street Suite 300 Lowell MA MASSACHUSETTS 01852 Director David Donabedian 116 John Street Suite 300 Lowell MA MASSACHUSETTS 01852 Director Cameron Durrant 116 John Street Suite 300 Lowell MA MASSACHUSETTS 01852 Director Edgar D. Jannotta 116 John Street Suite 300 Lowell MA MASSACHUSETTS 01852 Director Stephen Oesterle 116 John Street Suite 300 Lowell MA MASSACHUSETTS 01852 Director Norbert Riedel 116 John Street Suite 300 Lowell MA MASSACHUSETTS 01852 Director Other Health Care Decline to Disclose 06b false 2023-11-07 false true true true false 0 Brookline Capital Markets 44656 Arcadia Securities, LLC 44656 1370 Avenue of the Americas 29th Fl New York NY NEW YORK 10019 SC SOUTH CAROLINA HI HAWAII WY WYOMING IL ILLINOIS TX TEXAS NC NORTH CAROLINA FL FLORIDA NY NEW YORK VA VIRGINIA MI MICHIGAN NJ NEW JERSEY CA CALIFORNIA true 31608219 17257814 14350405 Includes conversion of outstanding Convertible Notes into shares of Preferred Stock. false 22 0 252750 true 0 true false Alcyone Therapeutics, Inc. PJ Anand PJ Anand Chief Executive Officer 2023-11-22